Skip to main content
. 2023 May 12. Online ahead of print. doi: 10.1016/j.jaip.2023.05.005

Figure 3.

Figure 3

Products analyzed by expiration year for IgG binding activities against (A) recombinant SARS-CoV-2 RBD, (B) spike, and (C) NP using ELISA. Graph represents the number of samples testing positive and negative for binding to SARS-CoV-2 proteins. A clear upward trend emerges, with approximately 60% and 85% of the Ig products with expiration dates of 2023 and 2024 testing positive for binding to SARS-CoV-2 proteins, respectively.